Paediatric medicine TOP20 comes out! 18 brands sold more than 30% of 4 000 products

Medicine network May 22, the children's drug market again welcomed the goodThe CDE website publishes the Technical Guidelines for Real World Evidence in Support of The Development and Review of Children's Medicines (Draft for Comments), which apply to all types of children's medicines, including chemicals, Chinese medicines and biological productsAccording to minet data, sales of chinese medicine pediatric drugs at the end of China's public medical institutions reached nearly 9 billion yuan in 2019, up 11.61 percent year-on-yearProduct TOP20, 13 are exclusive products, children cough ingling oral solution, pediatric lung fever wheezing particles and other 4 products sales growth of more than 30%;In recent years, china's public medical institutions terminal sales of traditional Chinese medicine pediatric drugs (unit: million yuan)meters of the net data show that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal sales growth rate of chinese medicine pediatric drug market has remained at more than 10%, in 2019 reached 8.905 billion yuanAmong them, the product TOP20 sales accounted for nearly 70%, the market concentration is high2019 China's public medical institutions terminal Chinese medicine pediatric drug products TOP20 (unit: million yuan)products TOP20, 13 are exclusive products, 18 sales of more than 100 million yuan, more than 1 in 2018In subcategory, pediatric cough and sputum drugs were the most, up to 11, followed by pediatric cold drugs, there are 6in 2019 China's public medical institutions terminal chinese medicine pediatricsbrand TOP20 (units: 10,000 yuan)brand TOP20, 18 sales of more than 100 million yuan, and the top three growth rate of more than 20%Jichuan Pharmaceutical's children's hot particles have been at the top of the list for many years, Jiangsu Kangyuan Pharmaceutical's Jin Zhen oral liquid sales exceeded 500 million, Guizhou Sanli Pharmaceutical's laryngeal sword spray (child type) is the only approved child oral throat disease spray type approved by the State Drug AdministrationIn recent years, China's public medical institutions terminal children's hot particles sales (unit: million yuan)children's yuqing hot particles for the exclusive varieties of Jichuan pharmaceutical industry, the main treatment of children's hot and cold In recent years, the pediatric sage hot particles in China's public medical institutions terminal in the pharmaceutical pediatric drug market has been the first, sales in 2018 exceeded 1 billion, in 2019 reached a new high of 1,476 million yuan, an increase of 21.96 percent year-on-year Jichuan Pharmaceuticals in the 2019 annual report mentioned that the company's core products, pandiblue anti-inflammatory oral solution, Rebeirapyrin sodium intestinal capsules and pediatric sage heat particles continue to maintain rapid growth and market-leading scale advantage At the same time, the company's products selected a number of drug guidelines, consultation consensus and teaching materials Such as the pandi blue anti-inflammatory oral solution was issued by the Henan Provincial Administration of Traditional Chinese Medicine, "Henan Province adult influenza in the
prevention and control program (2019 edition)" and "Henan Province Children's Influenza Prevention and Control Program (2019 Edition)" listed as adult and children's influenza prevention and treatment drugs, children's disease is listed as children's influenza prevention and treatment drugs, this is following the National Health and Health Commission Office, the National Chinese medicine After the "Influenza Diagnosis and Treatment Program (2018 Edition), (2018 Revision), jiangsu Province Chinese Medicine Bureau issued the "China Medicine Treatment Program for Influenza in Jiangsu Province (2018 Edition)," the efficacy of the epidemic anti-inflammatory oral fluid and children's hot particles to prevent influenza was once again recognized by the authorities 　　In recent years, China's public medical institutions terminal Jin Zhen oral liquid sales (unit: million yuan) Jin Zhen oral liquid is the exclusive productof of Kangyuan Pharmaceutical, sales in recent years rose rapidly After 2017 sales of 200 million yuan, 2019 exceeded the scale of 500 million, an increase of more than 30% year-on-year Jin Zhen oral solution for acute bronchitis in children in line with sputum fever cough, the performance of fever, cough, coughing yellow sputum, cough unpleasant cough, tongue redness and so on According to kangyuan PharmaceuticalS Annual Report shows that the company around the listed Chinese medicine varieties, the continuous accumulation of clinical re-evaluation and basic research evidence, to further clarify its effectiveness and safety, and continue to carry out the efficacy of several varieties represented by JinZhen oral liquid and mechanism of action interpretation 　　In recent years, china's public medical institutions terminal open throat sword inhaler sales (unit: million yuan) meters of internal network data show that in 2019 China's public medical institutions terminal open throat sword inhaler sales reached 624 million yuan, an increase of 22.60 percent year-on-year Among them, the larynx spray (children's type) accounted for more than 80% on April 28 this year, Guizhou Sanli Pharmaceuticals successfully landed A shares Data show that the laryngeal sword spray (child type) is the exclusive variety of Guizhou Sanli Pharmaceutical, belongs to the pediatric respiratory system and oral medicine, is currently mainly used for the treatment of children's throat disease, is the state drug administration's only approved children's oral throat disease spray type, has been included in the national medical insurance catalog varieties, and has entered Guizhou, Guangxi, Guangdong, Zhejiang and other local basic drugs directory By the end of 2019, the laryngeal sword spray (child type) has covered 323 cities, 1696 counties, covering a total of 138,474 terminals, including 4689 grade , 8621 primary health care terminals, 26,512 clinics, and other retail terminals 98,652 At the same time, more than 96 per cent of children's specialist hospitals in the country have been covered source: Mi net database, listed company announcement note: if there are omissions, welcome to point the right!